Cryptococcal Meningitis in Senegal: Epidemiology, Laboratory Findings, Therapeutic and Outcome of Cases Diagnosed from 2004 to 2011

Abstract

Early diagnosis is essential to control cryptococcosis, and countries should prioritize widespread and reliable access to rapid diagnostic cryptococcus antigen assays. But it is important to make available conventional methods (India ink and culture) in the maximum of laboratory in regional health facilities.

Evaluation of ventriculoperitoneal shunt in the treatment of intracranial hypertension in the patients with cryptococcal meningitis: A report of 12 cases

“…From the end of the 20th century, with the increase of AIDS, CM incidence has grown. Foreign papers report that CM is usually caused by hypoimmunity, so most patients with CM have AIDS [11,12]. However, in this study, there were no patients with AIDS or other immunodeficiency disorders, which is different from foreign reports.…”

Usefulness of MALDI-TOF Mass Spectrometry for Routine Identification of Candida Species in a Resource-Poor Setting

“…This reduced delay is comparable to those published in the literature despite some little differences in the average hands-on time per isolate varying according to extraction protocol used, the type of microorganism to be identified and the type of instrumentation platform [27]. Ultimately, this time saving will be greatly useful in the future in the clinical management of invasive fungal diseases such as candidemia and cryptococcal meningitis characterized by delay in diagnosis and high mortality rate [28][29][30].…”

MLST-Based Population Genetic Analysis in a Global Context Reveals Clonality amongst Cryptococcus neoformans var. grubii VNI Isolates from HIV Patients in Southeastern Brazil

“…In Africa, despite the increasing availability of ART and amphotericin B in some regions, the mortality rate varies from 17 to 62% [11–14]. Despite ART being provided free of charge by the public health service and thus readily available in Brazil, the mortality in the first week of admission is still 42–51%, which is attributed to the advanced immunosuppression at start of HIV treatment and late diagnosis [9, 15].…”